Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Terminated 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Burkitt Lymphoma 1

Interventions

Cisplatin 517 Radiotherapy 378 Cyclophosphamide 368 Carboplatin 359 Capecitabine 342 Paclitaxel 337 Oxaliplatin 336 Gemcitabine 322 Docetaxel 317 Fluorouracil 290 Drug Therapy 276 Bevacizumab 248 apatinib 247 camrelizumab 219 Etoposide 201 Irinotecan 182 Doxorubicin 181 Leucovorin 163 Dexamethasone 161 pembrolizumab 153 Neoadjuvant Therapy 146 sintilimab 145 anlotinib 140 Blood Specimen Collection 140 Pemetrexed 138 Cytarabine 138 toripalimab 133 Surgical Procedures, Operative 131 Radiosurgery 131 S 1 (combination) 125

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × veltuzumab × Clear all

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡